These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37436074)

  • 1. PSMC4 promotes prostate carcinoma progression by regulating the CBX3-EGFR-PI3K-AKT-mTOR pathway.
    Liu K; Zhang S; Gong Y; Zhu P; Shen W; Zhang Q
    J Cell Mol Med; 2023 Aug; 27(16):2437-2447. PubMed ID: 37436074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA RHPN1-AS1 inhibition induces autophagy and apoptosis in prostate cancer cells via the miR-7-5p/EGFR/PI3K/AKT/mTOR signaling pathway.
    Ma X; Ren H; Zhang Y; Wang B; Ma H
    Environ Toxicol; 2022 Dec; 37(12):3013-3027. PubMed ID: 36125241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
    Yan G; Ru Y; Wu K; Yan F; Wang Q; Wang J; Pan T; Zhang M; Han H; Li X; Zou L
    Prostate; 2018 Feb; 78(3):166-177. PubMed ID: 29181846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling.
    Ding X; Xu X; He XF; Yuan Y; Chen C; Shen XY; Su S; Chen Z; Xu ST; Huang YH
    Bioengineered; 2021 Dec; 12(1):803-814. PubMed ID: 33648424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribosomal protein L22-like1 promotes prostate cancer progression by activating PI3K/Akt/mTOR signalling pathway.
    Yi X; Zhang C; Liu B; Gao G; Tang Y; Lu Y; Pan Z; Wang G; Feng W
    J Cell Mol Med; 2023 Feb; 27(3):403-411. PubMed ID: 36625246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.
    Li L; Hu Y; Chen D; Zhu J; Bao W; Xu X; Chen H; Chen W; Feng R
    Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34791506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EHMT2 promotes the development of prostate cancer by inhibiting PI3K/AKT/mTOR pathway.
    Fan HT; Shi YY; Lin Y; Yang XP
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7808-7815. PubMed ID: 31599405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.
    Ma T; Chen H; Wang P; Yang N; Bao J
    Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162
    [No Abstract]   [Full Text] [Related]  

  • 9. Hydroxysafflor Yellow A Promotes HaCaT Cell Proliferation and Migration by Regulating HBEGF/EGFR and PI3K/AKT Pathways and Circ_0084443.
    Zhang Y; Xiao YW; Ma JX; Wang AX
    Chin J Integr Med; 2024 Mar; 30(3):213-221. PubMed ID: 37688744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analyzing roles of small nucleolar RNA host gene 25 from clinical, molecular target and tumor formation in prostate cancer.
    Liu Z; Ke S; Wang Q; Gu X; Zhai G; Shao H; He M; Guo J
    Exp Cell Res; 2023 Aug; 429(2):113686. PubMed ID: 37307941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tideglusib promotes wound healing in aged skin by activating PI3K/Akt pathway.
    Sun J; Zhao H; Shen C; Li S; Zhang W; Ma J; Li Z; Zhang M; Yang J
    Stem Cell Res Ther; 2022 Jun; 13(1):269. PubMed ID: 35729652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway.
    Liang F; Yue J; Wang J; Zhang L; Fan R; Zhang H; Zhang Q
    Med Oncol; 2015 Mar; 32(3):49. PubMed ID: 25636507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.
    Zheng J; Liu C; Shi J; Wen K; Wang X
    Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of MicroRNA miR-101-3p on prostate cancer progression by regulating Cullin 4B (CUL4B) and PI3K/AKT/mTOR signaling pathways.
    Gu Z; You Z; Yang Y; Ding R; Wang M; Pu J; Chen J
    Bioengineered; 2021 Dec; 12(1):4719-4735. PubMed ID: 34338146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasopharyngeal carcinoma with non-squamous phenotype may be a variant of nasopharyngeal squamous cell carcinoma after inhibition of EGFR/PI3K/AKT/mTOR pathway.
    Wang J; Shang Y; Wang Y; Li Y; Wang L; Huang S; Lyu X
    Histol Histopathol; 2024 May; 39(5):647-657. PubMed ID: 37971211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-218-5p inhibit the migration and proliferation of pterygium epithelial cells by targeting EGFR via PI3K/Akt/mTOR signaling pathway.
    Han S; Chen Y; Gao Y; Sun B; Kong Y
    Exp Eye Res; 2019 Jan; 178():37-45. PubMed ID: 30243568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-129 inhibits cell proliferation and metastasis by targeting ETS1 via PI3K/AKT/mTOR pathway in prostate cancer.
    Xu S; Ge J; Zhang Z; Zhou W
    Biomed Pharmacother; 2017 Dec; 96():634-641. PubMed ID: 29035829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis.
    Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X
    Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.